Sugi Predict

Sugi Predict / Compounds / SCHEMBL330170

SCHEMBL330170

SCHEMBL330170

CC(C)(C)c1nc(NC(=O)c2cc(Cl)ccc2O)sc1C#N

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS4 Q9NRS4 9/20 0.51
▸ KCNMA1 Q12791 4/20 0.49
▸ P2RX1 P51575 11/20 0.48
▸ P2RX4 Q99571 5/20 0.44
▸ P2RX7 Q99572 5/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ IKBKB O14920 1/20 0.42
▸ CHUK O15111 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MYLK Q15746 1/20 0.42
▸ MAP4K5 Q9Y4K4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330465 0.87 TMPRSS4 (0.42) TMPRSS4MEN1KMT2A
SCHEMBL330373 0.81 KCNMA1 (0.50) TMPRSS4KCNMA1P2RX1P2RX4P2RX7
SCHEMBL13055757 0.75 TMPRSS4 (0.51) TMPRSS4KCNMA1P2RX1P2RX4P2RX7
SCHEMBL15916250 0.74 RAB9A (0.67) TMPRSS4KCNMA1P2RX1P2RX4P2RX7
SCHEMBL17770408 0.74 DYRK1A (0.61) TMPRSS4P2RX1MAP4K5
SCHEMBL17770446 0.74 TMPRSS4 (0.59) TMPRSS4KCNMA1P2RX1P2RX4P2RX7
SCHEMBL9893065 0.73 DYRK1A (0.45) MEN1KMT2A
SCHEMBL8553290 0.72 LRRK2 (0.49) MEN1KMT2A
SCHEMBL9892348 0.72 ALDH1A1 (0.43) MEN1KMT2A
SCHEMBL331430 0.71 MAPT (0.53) TMPRSS4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503425-B2 Methods of treating or controlling cytotoxic cerebral edema AEROMICS, INC. (US) 2025-12-23 — — US disclosed
US-20240360077-A1 METHODS AEROMICS, INC. 2024-10-31 — — US disclosed
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AEROMICS, INC. (US) 2024-01-16 — — US disclosed
US-20220081391-A1 METHODS AEROMICS, INC. 2022-03-17 — — US disclosed
CN-109512805-B Compounds for the treatment of aquaporin mediated diseases 埃罗米克斯公司 2021-12-31 — — CN disclosed
US-11084778-B2 Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia AEROMICS, INC. (US) 2021-08-10 — — US disclosed
US-20180334424-A1 METHODS AEROMICS, INC. 2018-11-22 — — US disclosed
EP-2846787-B1 Compounds for use in the treatment of aquaporin-mediated diseases AEROMICS INC (US) 2018-08-29 — — EP disclosed
US-9994514-B2 Methods of treating cerebral edema and spinal cord edema AEROMICS, INC. (US) 2018-06-12 — — US disclosed
US-9949991-B2 Methods of treating aquaporin-mediated conditions AEROMICS, INC. (US) 2018-04-24 — — US disclosed
US-20060014811-A1 Medicament for treatment of cancer INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-01-19 — — US disclosed
EP-1555018-A1 REMEDIES FOR NEURODEGENERATIVE DISEASES Institute of Medicinal Molecular Design, Inc. (JP) 2005-07-20 — — EP disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1535610-A1 THERAPEUTIC AGENT FOR CANCER Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 — — EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 — — EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 — — EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 — — US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180334424-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1257/4885KCNMA1 627/4885P2RX1 2910/4885
US-12503425-B2 Methods of treating or controlling cytotoxic cerebral edema AQP4, AQP1, AQP3 TMPRSS4 1043/4885KCNMA1 631/4885P2RX1 2714/4885
US-20220081391-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1257/4885KCNMA1 627/4885P2RX1 2910/4885
US-20060014811-A1 Medicament for treatment of cancer HDAC3, HDAC1, HDAC6 TMPRSS4 3353/4885KCNMA1 2192/4885P2RX1 4850/4885
US-11084778-B2 Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia AQP4, AQP1, AQP3 TMPRSS4 946/4885KCNMA1 398/4885P2RX1 2805/4885
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AQP4, AQP1, AQP3 TMPRSS4 1444/4885KCNMA1 827/4885P2RX1 3317/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB TMPRSS4 3292/4885KCNMA1 2705/4885P2RX1 2316/4885
US-20240360077-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1415/4885KCNMA1 662/4885P2RX1 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.